CJC-1295 No DAC

What Is CJC-1295 No DAC?

CJC-1295 No DAC is a synthetic version of the first 29 amino acids of growth hormone-releasing hormone (GHRH), the natural signal the body uses to prompt the pituitary gland to release growth hormone. It's built with a few amino acid substitutions designed to resist the enzymes that would normally break it down quickly in the bloodstream.

The "No DAC" part of the name distinguishes it from CJC-1295 with DAC, a related but chemically different version that includes a drug affinity complex allowing it to bind to albumin in the blood and remain active for days. Without that modification, No DAC clears the body much faster and is generally studied for producing a shorter, more pulsatile pattern of activity that more closely resembles the body's natural GHRH release.

What CJC-1295 No DAC Is Being Researched For

• Growth Hormone Release

  The core area of research is how CJC-1295 No DAC activates the GHRH receptor on the pituitary gland, which is the first step in the body's natural growth hormone release process.^[1][2]

• Pulsatile Signaling Patterns

  Because it clears the body quickly, researchers have studied CJC-1295 No DAC for how closely it mirrors the body's own pulsatile release pattern, compared to longer-acting versions that produce more sustained activity.

• Combination Research

  CJC-1295 No DAC is frequently studied alongside other growth hormone secretagogues, such as Ipamorelin, since the two act on separate receptors that both feed into growth hormone release.

How CJC-1295 No DAC Works

• Activating the GHRH Receptor

  Research points to CJC-1295 No DAC binding to the GHRH receptor on pituitary cells, which triggers a chain of internal signaling that leads to growth hormone release. This is the same receptor the body's own GHRH activates naturally.^[1][2]

• Resisting Rapid Breakdown

  Research points to a handful of specific amino acid substitutions in the CJC-1295 sequence that make it more resistant to the enzymes that would otherwise break it down within minutes, giving researchers a more workable window to study its effects compared to unmodified GHRH fragments.^[2]

Reconstitution and Handling

CJC-1295 No DAC is typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

CJC-1295 No DAC stands out among GHRH analogs for its short activity window, which researchers generally tie to a more natural, pulsatile pattern of growth hormone signaling compared to longer-acting versions. Its core research base centers on GHRH receptor activation and resistance to rapid enzymatic breakdown. Most available data still comes from animal and cell models, with human research concentrated on the longer-acting DAC version.

Frequently Asked Questions

Sources and Research

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
2. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29 albumin bioconjugates activate the GRF receptor on the pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058.